Review
Version 1
Preserved in Portico This version is not peer-reviewed
Clinical Perspectives of Theranostics
Version 1
: Received: 12 February 2021 / Approved: 15 February 2021 / Online: 15 February 2021 (14:55:01 CET)
Version 2 : Received: 18 February 2021 / Approved: 22 February 2021 / Online: 22 February 2021 (07:51:33 CET)
Version 2 : Received: 18 February 2021 / Approved: 22 February 2021 / Online: 22 February 2021 (07:51:33 CET)
How to cite: Tamaki, N.; Okamoto, S.; Shiga, T. Clinical Perspectives of Theranostics. Preprints 2021, 2021020314. https://doi.org/10.20944/preprints202102.0314.v1 Tamaki, N.; Okamoto, S.; Shiga, T. Clinical Perspectives of Theranostics. Preprints 2021, 2021020314. https://doi.org/10.20944/preprints202102.0314.v1
Abstract
Theranostics covers combination of diagnostic and therapeutic techniques for various cancers throughout body using suitable drug combination. This review covers well-known treatment of thyroid cancer and pheochromocytoma with I-131 compounds and also new radiopharmaceuticals for prostatic cancer and pancreatic cancer. Of particular, new trends toward patient outcome has been focused. The theranostics will become an ever-increasing part of clinical nuclear medicine these days.
Keywords
PET, Theranostics, Radiopharmaceuticals
Subject
Medicine and Pharmacology, Immunology and Allergy
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
